SCHEMBL6463048

SCHEMBL6463048

Cc1onc(-c2c(F)cccc2Cl)c1C(=O)NC1CCC(Nc2nccc(N(C)C)n2)CC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 1/20 0.55
POLB P06746 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
ALDH1A1 P00352 4/20 0.49
MAPT P10636 1/20 0.49
HPGD P15428 1/20 0.49
GLA P06280 1/20 0.49
MAPK8 P45983 1/20 0.49
MAPK14 Q16539 1/20 0.49
NPC1 O15118 1/20 0.49
LMNA P02545 1/20 0.49
HSD17B10 Q99714 1/20 0.48
KDM4E B2RXH2 1/20 0.48
KMT2A Q03164 2/20 0.48
ALOX15 P16050 1/20 0.47
GPBAR1 Q8TDU6 1/20 0.47
MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6463041 1.00 GHSR (0.55) GHSRPOLBSMN1; SMN2ALDH1A1MAPT
SCHEMBL6461553 0.95 GHSR (0.61) GHSRALDH1A1MAPTMAPK8MAPK14
SCHEMBL6461560 0.95 GHSR (0.61) GHSRALDH1A1MAPTMAPK8MAPK14
SCHEMBL6867574 0.88 KMT2A (0.64) GHSRSMN1; SMN2ALDH1A1MAPTMAPK8
SCHEMBL6867571 0.88 KMT2A (0.64) GHSRSMN1; SMN2ALDH1A1MAPTMAPK8
SCHEMBL4262247 0.84 GHSR (0.55) GHSRPOLBSMN1; SMN2ALDH1A1MAPT
SCHEMBL4262243 0.84 GHSR (0.55) GHSRPOLBSMN1; SMN2ALDH1A1MAPT
SCHEMBL6461762 0.82 HTT (0.53) GHSRPOLBSMN1; SMN2ALDH1A1MAPT
SCHEMBL13793328 0.82 MCHR1 (0.64) GHSRPOLBALDH1A1KDM4EKMT2A
SCHEMBL6461754 0.82 HTT (0.53) GHSRPOLBSMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US claimed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO claimed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP claimed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 GHSR 388/4885POLB 3369/4885SMN1; SMN2 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.